Moon Hyung-Sik, Jung Shin, Jung Tae-Young, Cao Van Thang, Moon Kyung-Sub, Kim In-Young
Department of Neurosurgery, Chonnam National University Hwasun Hospital & Medical School, Gwangju, Korea.
J Korean Neurosurg Soc. 2010 Jan;47(1):11-6. doi: 10.3340/jkns.2010.47.1.11. Epub 2010 Jan 31.
Abnormalities of the bone are frequently encountered in patients with meningioma, and hyperostosis and endostosis are common bone alterations in these tumors. Extensive bony destruction is very unusual in patients with meningioma. We report six cases of intracranial meningioma associated with an osteolytic lesion of the skull and discuss the underlying mechanisms that may be responsible for bone destruction in patients with meningioma.
Six patients were classified into three groups, severe, moderate and mild, according to the degree of osteolytic bony destruction. The tumor was classified as intracranial or extracranial, depending on its location. We investigated the potential role of matrix metalloproteinase (MMP) in meningioma-associated osteolysis. The levels of MMP expression were determined by gelatin zymography, reverse transcription-quantitative PCR analysis (RT-PCR) and immunohistochemical analysis.
Complete surgical removal of the lesion was performed in each patient. Histological examination revealed benign meningioma in four cases, and two cases of atypical meningioma. Patients did not have a poor prognosis except one case of recurred atypical meningioma. Gelatin zymography and RT-PCR detected high levels of MMP-2 in almost all extracranial masses in comparison with the intracranial masses and MMP-9 in two. There was no difference in the severity of bone destruction. Immunohistochemical analysis revealed MMP-2 expression in the vicinity of the bone destruction, and a few MMP-9-positive stainings were observed.
Osteolysis of the skull in patients with meningiomas might not be indicative of malignant pathological features and poor prognosis. Invasion to the extracranial portion and osteolysis might be associated with MMP-2 expression in meningioma.
脑膜瘤患者常出现骨骼异常,骨质增生和骨内膜增生是这些肿瘤常见的骨质改变。广泛的骨质破坏在脑膜瘤患者中非常少见。我们报告6例颅内脑膜瘤合并颅骨溶骨性病变的病例,并探讨可能导致脑膜瘤患者骨质破坏的潜在机制。
根据溶骨性骨质破坏程度将6例患者分为重度、中度和轻度三组。根据肿瘤位置将其分为颅内或颅外肿瘤。我们研究了基质金属蛋白酶(MMP)在脑膜瘤相关骨质溶解中的潜在作用。通过明胶酶谱法、逆转录定量聚合酶链反应分析(RT-PCR)和免疫组织化学分析来测定MMP表达水平。
每位患者均接受了病变的完整手术切除。组织学检查显示4例为良性脑膜瘤,2例为非典型脑膜瘤。除1例复发性非典型脑膜瘤外,患者预后均良好。与颅内肿块相比,明胶酶谱法和RT-PCR检测到几乎所有颅外肿块中MMP-2水平较高,2个肿块中MMP-9水平较高。骨质破坏的严重程度无差异。免疫组织化学分析显示骨质破坏附近有MMP-2表达,观察到少数MMP-9阳性染色。
脑膜瘤患者颅骨骨质溶解可能并不提示恶性病理特征和不良预后。向颅外部分侵犯和骨质溶解可能与脑膜瘤中MMP-2表达有关。